MAbgène will become LFB Biomanufacturing starting January 1st 2012….

In 2007, LFB (Laboratoire Français du Fractionnement et des Biotechnologies) acquired MAbgène with a double objectives :

     - Build in house capacities for the manufacturing of MAbs from its own pipeline,
     - Grow a CMO (Contract Manufacturing Organization) business with third parties,
       in a very competitive environment, but with strong growth drivers.

Since then, LFB has continuously invested in MAbgène (mainly on the site of Alès, south of France) and optimized the organization of its biomanufacturing capabilities.

Development activities are transferred from Lille to Alès respectively for Pilot labs in 2010, and CLD (cell line development) labs in 2011. These transfers enabled MAbgène to offer a wide range of CMO services, covering all steps from early stage development to commercial manufacturing.

Additional GMP manufacturing capacities are built. MAbgène will be equipped with two bioreactors suites of 300l, one of them using disposable technology, and another 1000l disposable suite. Manufacturing supports are also strengthened (QA, QC, logistics, etc…) in order to bring the whole facility to FDA compliance in 2013. These achievements are key for MAbgène going international.

Lastly, our alliance with Sanofi to build up a common production platform will enable to offer all the relevant CMO services from two complementary manufacturing sites located in France.

On January 1st 2012 MAbgène’s name will change, and the company will become LFB Biomanufacturing (www.lfbbiomanufacturing.com). This new brandname reflects the fully accomplished integration process of the company and materializes the new production activities within LFB.

A new development era is now starting. LFB Biomanufacturing will engage for the best customer services, relying on each of its employees’ professionalism within the strategic framework and the key values of LFB Group.

We would like to take this opportunity to wish you a Merry Christmas and a Happy New Year 2012.

Sincerely yours,  

                            Evelyne Nguyen                                                    Marc Vouillamoz
                            President                                                               CEO